{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:21:22Z","timestamp":1788664882507,"version":"build-2803163510"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["BI trial numbers: 1447-0001; 1447-0002; 1447-0004"],"award-info":[{"award-number":["BI trial numbers: 1447-0001; 1447-0002; 1447-0004"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>BI 1569912 is an orally administered, GluN2B-selective negative allosteric modulator at the N-methyl-D-aspartate receptor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To investigate the safety, tolerability and pharmacokinetics (PK) of BI 1569912 in healthy males across three partially randomised, placebo-controlled, parallel-group phase I trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Trial 1 evaluated single rising doses (SRD) of BI 1569912 versus placebo in Germany and assessed formulation and food effects on bioavailability. Trial 2 evaluated multiple rising doses (MRD) of BI 1569912 versus placebo in young and elderly participants in Germany. Trial 3 investigated single rising and multiple doses (MD) of BI 1569912 in participants in Japan, including PK to assess morning versus evening dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Trial completion\/randomisation numbers were: Trial 1 (SRD part, 54\/55; bioavailability\/food effect part, 8\/13); Trial 2 (MRD part, 71\/71; Elderly part, 12\/12); Trial 3 (SRD part, 32\/32; MD part, 12\/12; evening PK part, 12\/12). No deaths, serious adverse events (AEs), AEs of special interest, or discontinuations because of AEs were reported. There was no clinical evidence clearly suggestive of dissociation. After oral administration, BI 1569912 was rapidly absorbed and eliminated, with dose-proportional increases in plasma exposure. Formulation (oral solution vs tablet) did not affect PK. Administration with food reduced\n                      <jats:italic toggle=\"yes\">C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      and delayed\n                      <jats:italic toggle=\"yes\">T<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      without affecting AUC; likewise, evening dosing lowered\n                      <jats:italic toggle=\"yes\">C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      versus morning while AUC remained similar. Steady state was achieved by Day 3 of multiple dosing. Exposure was similar between young and elderly participants. Urinary excretion of unchanged drug was negligible.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>BI 1569912 demonstrated favourable safety and PK profiles in healthy participants.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Clinical trial registration:<\/jats:bold>\n                      Trial 1 (ClinicalTrials.gov: NCT04445090 (1447-0001)); Trial 2 (ClinicalTrials.gov: NCT04978506 (1447-0002)); Trial 3 (ClinicalTrials.gov: NCT04958252 (1447-0004)).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261481073","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:38:30Z","timestamp":1788352710000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials"],"prefix":"10.1177","author":[{"given":"Andreas","family":"H\u00fcnnemeyer","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Biberach an der Riss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Ogama","sequence":"additional","affiliation":[{"name":"SOUSEIKAI Sumida Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"De Crescenzo","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer-Georg","family":"Goeldner","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Biberach an der Riss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Harada","sequence":"additional","affiliation":[{"name":"Nippon Boehringer Ingelheim Co. Ltd, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Katakabe","sequence":"additional","affiliation":[{"name":"Nippon Boehringer Ingelheim Co. Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Scholz","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Shatillo","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9648-3831","authenticated-orcid":false,"given":"Sigurd D.","family":"S\u00fcssmuth","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Biberach an der Riss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Keicher","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Research Organisation GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"crossref","unstructured":"Abdallah CG Sanacora G Duman RS et al. (2015) Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annual Review of Medicine 66: 509\u2013523. https:\/\/doi.org\/10.1146\/annurev-med-053013-062946","DOI":"10.1146\/annurev-med-053013-062946"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Addy C Assaid C Hreniuk D et al. (2009) Single-dose administration of MK-0657 an NR2B-selective NMDA antagonist does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson\u2019s disease. Journal of Clinical Pharmacology 49: 856\u2013864. https:\/\/doi.org\/10.1177\/0091270009336735","DOI":"10.1177\/0091270009336735"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Burnell ES Irvine M Fang G et al. (2019) Positive and negative allosteric modulators of N-methyl-d-aspartate (NMDA) receptors: Structure\u2013activity relationships and mechanisms of action. Journal of Medicinal Chemistry 62(1): 3\u201323. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01640","DOI":"10.1021\/acs.jmedchem.7b01640"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Cui L Li S Wang S et al. (2024) Major depressive disorder: Hypothesis mechanism prevention and treatment. Signal Transduction and Targeted Therapy 9(1): 30. https:\/\/doi.org\/10.1038\/s41392-024-01738-y","DOI":"10.1038\/s41392-024-01738-y"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Cui Y Jin J Zhang X et al. (2011) Forebrain NR2B overexpression facilitating the prefrontal cortex long-term potentiation and enhancing working memory function in mice. PLoS One 6(5): e20312. https:\/\/doi.org\/10.1371\/journal.pone.0020312","DOI":"10.1371\/journal.pone.0020312"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Cull-Candy SG Leszkiewicz DN (2004) Role of distinct NMDA receptor subtypes at central synapses. Science\u2019s STKE 2004(255): re16. https:\/\/doi.org\/10.1126\/stke.2552004re16","DOI":"10.1126\/stke.2552004re16"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Duman RS (2014) Pathophysiology of depression and innovative treatments: Remodeling glutamatergic synaptic connections. Dialogues in Clinical Neuroscience 16(1): 11\u201327. https:\/\/doi.org\/10.31887\/DCNS.2014.16.1\/rduman","DOI":"10.31887\/DCNS.2014.16.1\/rduman"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Duman RS Aghajanian GK (2012) Synaptic dysfunction in depression: Potential therapeutic targets. Science 338(6103): 68\u201372. https:\/\/doi.org\/10.1126\/science.1222939","DOI":"10.1126\/science.1222939"},{"key":"e_1_3_3_10_1","volume-title":"Food and Drug Administration guidance for industry: Food-effect bioavailability and fed bioequivalence studies","author":"FDA","year":"2002","unstructured":"FDA (2002) Food and Drug Administration guidance for industry: Food-effect bioavailability and fed bioequivalence studies. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)."},{"key":"e_1_3_3_11_1","volume-title":"E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs","author":"FDA","year":"2005","unstructured":"FDA (2005) E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs."},{"key":"e_1_3_3_12_1","volume-title":"Center for drug evaluation and research","author":"FDA","year":"2018","unstructured":"FDA (2018) Center for drug evaluation and research. Spravato (Esketamine), NDA 211243, Janssen Pharmaceuticals, Inc."},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Feyissa AM Chandran A Stockmeier CA et al. (2009) Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33(1): 70\u201375. https:\/\/doi.org\/10.1016\/j.pnpbp.2008.10.005","DOI":"10.1016\/j.pnpbp.2008.10.005"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Gerhard DM Pothula S Liu RJ et al. (2020) GABA interneurons are the cellular trigger for ketamine\u2019s rapid antidepressant actions. Journal of Clinical Investigation 130(3): 1336\u20131349. https:\/\/doi.org\/10.1172\/JCI130808","DOI":"10.1172\/JCI130808"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Gielen M Siegler Retchless B Mony L et al. (2009) Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 459(7247): 703\u2013707. https:\/\/doi.org\/10.1038\/nature07993","DOI":"10.1038\/nature07993"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Gomez-Mancilla B Levy JA Ganesan S et al. (2023) MIJ821 (onfasprodil) in healthy volunteers: First-in-human randomized placebo-controlled study (single ascending dose and repeated intravenous dose). Clinical and Translational Science 16(11): 2236\u20132252. https:\/\/doi.org\/10.1111\/cts.13623","DOI":"10.1111\/cts.13623"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Ibrahim L Diaz Granados N Jolkovsky L et al. (2012) A randomized placebo-controlled crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychopharmacology 32(4): 551\u2013557. https:\/\/doi.org\/10.1097\/JCP.0b013e31825d70d6","DOI":"10.1097\/JCP.0b013e31825d70d6"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"Kang HJ Voleti B Hajszan T et al. (2012) Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nature Medicine 18(9): 1413\u20131417. https:\/\/doi.org\/10.1038\/nm.2886","DOI":"10.1038\/nm.2886"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Lee MT Peng W-H Kan H-W et al. (2022) Neurobiology of depression: Chronic stress alters the glutamatergic system in the brain\u2014Focusing on AMPA receptor. Biomedicines 10(5): 1005. https:\/\/doi.org\/10.3390\/biomedicines10051005","DOI":"10.3390\/biomedicines10051005"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Machado-Vieira R Henter ID Zarate CAJr (2017) New targets for rapid antidepressant action. Progress in Neurobiology 152: 21\u201337. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.12.001","DOI":"10.1016\/j.pneurobio.2015.12.001"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"McIntyre RS Sanacora G Walling DP et al. (2025) Safety and efficacy of the NMDA-2b-selective negative allosteric modulator BI 1569912: A phase Ib randomized trial in major depressive disorder. Clinical Pharmacology & Therapeutics 118(5): 1202\u20131212. https:\/\/doi.org\/10.1002\/cpt.70018","DOI":"10.1002\/cpt.70018"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Monaco SA Gulchina Y Gao WJ (2015) NR2B subunit in the prefrontal cortex: A double-edged sword for working memory function and psychiatric disorders. Neuroscience and Biobehavioral Reviews 56: 127\u2013138. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.06.022","DOI":"10.1016\/j.neubiorev.2015.06.022"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Pal MM (2021) Glutamate: The master neurotransmitter and its implications in chronic stress and mood disorders. Frontiers in Human Neuroscience 15: 722323. https:\/\/doi.org\/10.3389\/fnhum.2021.722323","DOI":"10.3389\/fnhum.2021.722323"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Paoletti P Bellone C Zhou Q (2013) NMDA receptor subunit diversity: Impact on receptor properties synaptic plasticity and disease. Nature Reviews Neurosciences 14(6): 383\u2013400. https:\/\/doi.org\/10.1038\/nrn3504","DOI":"10.1038\/nrn3504"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Preskorn SH Baker B Kolluri S et al. (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist CP-101 606 in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology 28(6): 631\u2013637. https:\/\/doi.org\/10.1097\/JCP.0b013e31818a6cea","DOI":"10.1097\/JCP.0b013e31818a6cea"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Schultheis C Hoch A Just S et al. (2022) P285. Pharmacological effects of the novel NR2B modulator Bi 1569912 on electroencephalography and eye-tracking in a phase I study. Biological Psychiatry 91(9): S203. https:\/\/doi.org\/10.1016\/j.biopsych.2022.02.521","DOI":"10.1016\/j.biopsych.2022.02.521"},{"key":"e_1_3_3_27_1","doi-asserted-by":"crossref","unstructured":"Shelton RC Litman RE Hassman H et al. (2025) Rapid onset and sustained efficacy of onfasprodil (MIJ821) a novel NR2B negative allosteric modulator in patients with treatment-resistant depression: A phase 2 randomized placebo-controlled proof-of-concept study. Journal of Clinical Psychiatry 86(3): 23m15246. https:\/\/doi.org\/10.4088\/JCP.23m15246","DOI":"10.4088\/JCP.23m15246"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","unstructured":"Wang K Tan X Ding K-M et al. (2024) Dynamic regulation of phosphorylation of NMDA receptor GluN2B subunit tyrosine residues mediates ketamine rapid antidepressant effects. Pharmacological Research 205: 107236. https:\/\/doi.org\/10.1016\/j.phrs.2024.107236","DOI":"10.1016\/j.phrs.2024.107236"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Weed MR Bookbinder M Polino J et al. (2016) Negative allosteric modulators selective for the NR2B subtype of the NMDA receptor impair cognition in multiple domains. Neuropsychopharmacology 41(2): 568\u2013577. https:\/\/doi.org\/10.1038\/npp.2015.184","DOI":"10.1038\/npp.2015.184"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261481073","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261481073","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261481073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:51:07Z","timestamp":1788529867000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261481073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":28,"alternative-id":["10.1177\/02698811261481073"],"URL":"https:\/\/doi.org\/10.1177\/02698811261481073","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"02698811261481073"}}